Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).

[1]  M. Hadamitzky,et al.  Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial , 2018, European heart journal.

[2]  W. Qiu,et al.  Gender Differences in Outcomes and Predictors of All-Cause Mortality After Percutaneous Coronary Intervention (Data from United Kingdom and Sweden). , 2017, The American journal of cardiology.

[3]  Jun-Jie Zhang,et al.  High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention , 2016, BMC Cardiovascular Disorders.

[4]  E. Vicaut,et al.  Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.

[5]  N. Tang,et al.  Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: comment , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  J. Spertus,et al.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.

[7]  Chris I. Jones.  Platelet function and ageing , 2016, Mammalian Genome.

[8]  H. Suryapranata,et al.  Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor , 2016, Journal of thrombosis and haemostasis : JTH.

[9]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[10]  P. Noris,et al.  Platelet count and aging , 2014, Haematologica.

[11]  D. Atar,et al.  Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial , 2014, European heart journal.

[12]  A. Kastrati,et al.  Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[14]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[15]  C. Cannon,et al.  Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial , 2012 .

[16]  P. Teirstein,et al.  Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.

[17]  Douglas R Seals,et al.  Aging and vascular endothelial function in humans. , 2011, Clinical science.

[18]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[19]  V. Deneer,et al.  Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.

[20]  R. Koppensteiner,et al.  Adenosine diphosphate‐inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel , 2010, Journal of thrombosis and haemostasis : JTH.

[21]  A. Newman,et al.  The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. , 2009, Clinics in geriatric medicine.

[22]  P. Teirstein,et al.  Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. , 2009, American heart journal.

[23]  F. Verheugt,et al.  Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.

[24]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[25]  J. Ware,et al.  Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial , 2007, The Lancet.

[26]  B. Gersh,et al.  Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. , 2005, Journal of the American College of Cardiology.

[27]  J. Fleg,et al.  Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients ≥75 Years of Age): An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention , 2002, Circulation.

[28]  S. Yusuf,et al.  Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. , 2001, Journal of the American College of Cardiology.

[29]  Paul H. C. Eilers,et al.  Flexible smoothing with B-splines and penalties , 1996 .

[30]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.